Cerebellum’s Pfizer PFE Stock Holding History

Cerebellum’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,835	Closed	-$166K	–	532
2020 Q2	$166K	Buy	+4,835	New	+$164K	0.12%	59
2019 Q2	–	Sell	-63	Closed	-$3K	–	498
2019 Q1	$3K	Buy	63 +7	+13%	+$280	﹤0.01%	422
2018 Q4	$2K	Sell	56 -8	-13%	-$332	﹤0.01%	438
2018 Q3	$3K	Sell	64 -17	-21%	-$654	﹤0.01%	397
2018 Q2	$3K	Sell	81 -1,560	-95%	-$53.3K	0.01%	399
2018 Q1	$55K	Sell	1,641 -3,194	-66%	-$110K	0.07%	398
2017 Q4	$166K	Buy	+4,835	New	+$165K	0.12%	59

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cerebellum's PFE Position: Q3 2020 in Review

Cerebellum sold out of Pfizer (PFE) in Q3 2020, closing a stake of 4,835 shares — an estimated $166K sold.

Cerebellum first reported a position in PFE in Q4 2017 and held it in 7 quarters. The position peaked at $166K in Q2 2020. 2,508 funds tracked by Wall St. Rank hold PFE as of Q3 2020.

Cerebellum reported no remaining Pfizer position as of Q3 2020 after selling out during the quarter.
Cerebellum sold 4,835 Pfizer shares in Q3 2020, an estimated $166K.
Cerebellum first reported a position in Pfizer in Q4 2017 and held it in 7 quarters.
Cerebellum's Pfizer position peaked at $166K in Q2 2020.
2,508 funds tracked by Wall St. Rank held Pfizer as of Q3 2020.

Based on Cerebellum's 13F filing for Q3 2020, filed 21 Oct 2020.